Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

261. Cross sectional study: Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population

Cross sectional study: Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) or Hashimoto's thyroiditis relative to the general UK population Article Text Causation Cross sectional study Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population Philip E Knapp Statistics from Altmetric.com Commentary on: Boelaert K , Newby PR , Simmonds MJ , et al . Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease . Autoimmune thyroid disease, including Grave's disease

2010 Evidence-Based Medicine

262. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review

Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

263. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States Full Text available with Trip Pro

To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States To stimulate or withdraw? A cost-utility analysis of recombinant human (...) thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States Wang TS, Cheung K, Mehta P, Roman SA, Walker HD, Sosa JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD

2010 NHS Economic Evaluation Database.

264. Hemostasis in thyroid surgery: harmonic scalpel versus other techniques - a meta-analysis

Hemostasis in thyroid surgery: harmonic scalpel versus other techniques - a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

265. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Full Text available with Trip Pro

Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Mernagh P, Suebwongpat A, Silverberg J, Weston A Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of recombinant human thyroid-stimulating hormone (rhTSH) before radioiodine ablation in patients with low-risk thyroid cancer. The authors concluded

2010 NHS Economic Evaluation Database.

266. DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study Full Text available with Trip Pro

DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study In animal studies and a pilot trial in patients with congestive heart failure, the thyroid hormone analog 3,5 diiodothyropropionic acid (DITPA) had beneficial hemodynamic effects.This was a phase II multicenter, randomized, placebo-controlled, double-blind trial of New York Heart Association class II to IV congestive heart failure patients randomized (2:1 (...) frequent in the DITPA group. DITPA increased cardiac index (by 18%) and decreased systemic vascular resistance (by 11%), serum cholesterol (-20%), low-density lipoprotein cholesterol (-30%), and body weight (-11 lb). Thyroid-stimulating hormone was suppressed in patients given DITPA, which reflects its thyromimetic effect; however, no symptoms or signs of potential hypothyroidism or thyrotoxicosis were seen.DITPA improved some hemodynamic and metabolic parameters, but there was no evidence

2009 EvidenceUpdates Controlled trial quality: predicted high

267. Thyroid peroxidase antibodies in pregnant women with type 1 diabetes: impact on thyroid function, metabolic control and pregnancy outcome (Abstract)

Thyroid peroxidase antibodies in pregnant women with type 1 diabetes: impact on thyroid function, metabolic control and pregnancy outcome In pregnant women with type 1 diabetes, we evaluated whether the presence of thyroid peroxidase autoantibodies (anti-TPO) was associated with changes in thyroid function, metabolic control and pregnancy outcome.Prospective study, Denmark.Ninety-six consecutive pregnant women with type 1 diabetes. Twenty-five healthy pregnant controls.At 8, 14, 21, 27 and 33 (...) -TPO negative women. Twenty untreated anti-TPO positive women had higher TSH compared with untreated, anti-TPO negative women (p<0.05), but comparable free T4. At inclusion, 25% had TSH above the recommended treatment goal for levothyroxine (TSH>2.5 mIU/l), most prevalently among anti-TPO positive women. Sixteen women (17%) were treated for thyroid disorder during pregnancy. No differences were detected between the diabetic women with and without anti-TPO regarding HbA1C, insulin dose, median SMPG

2009 EvidenceUpdates

268. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. (Abstract)

Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases has been observed in follow-up studies. The management of this condition remains controversial. Most studies support blind radioactive iodine treatment while others negate this approach.To assess the effects of radioiodine therapy for differentiated thyroid (...) author entered data into a data extraction form and the second one verified the results of this procedure.Because of the absence of any suitable randomised or prospective controlled trial in this area, results currently cannot be presented.The currently available evidence is insufficient to reliably assess the potential of radioiodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

2009 Cochrane

269. High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. (Abstract)

High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. Congenital hypothyroidism (CHT) affects approximately one in 3000 to 4000 infants. CHT is one of the most common preventable causes of learning difficulties. Optimal management of CHT requires early diagnosis and prompt treatment to avoid abnormal neurodevelopmental outcome. One of the main issues in the management of CHT relates to the initial dose of levothyroxine to be used in order to achieve optimal (...) results in terms of intellectual development. Currently, it remains unclear whether high dose thyroid hormone replacement is more effective than low dose in the treatment of CHT. Further research is required to determine an appropriate dose that improves mental and psychomotor developmental outcomes.To determine the effects of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism.Randomised controlled trials were identified by searching The Cochrane Library, MEDLINE

2009 Cochrane

270. ACR-SNMMI-SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements

ACR-SNMMI-SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice (...) ) A. Radiopharmaceuticals 1. Radiopharmaceuticals taken up by the thyroid in proportion to thyroid function (see the ACR– SNM–SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements). a. Technetium-99m pertechnetate, given intravenously in an administered activity of 1 to 10 millicuries (37 to 370 MBq), depending on the protocol used, is trapped by the follicular cells of the thyroid. b. Iodine-123 (sodium iodide), given orally in an administered activity of 200 to 600 microcuries

2009 Society of Nuclear Medicine and Molecular Imaging

271. Revised American Thyroid Association Guidelines for DTC and Thyroid Nodule

Revised American Thyroid Association Guidelines for DTC and Thyroid Nodule ORIGINAL STUDIES, REVIEWS, AND SCHOLARLY DIALOG THYROID CANCER AND NODULES Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer David S. Cooper, M.D. 1 (Chair) * , Gerard M. Doherty, M.D., 2 Bryan R. Haugen, M.D., 3 Richard T. Kloos, M.D (...) ., 4 Stephanie L. Lee, M.D., Ph.D., 5 Susan J. Mandel, M.D., M.P.H., 6 Ernest L. Mazzaferri, M.D., 7 Bryan McIver, M.D., Ph.D., 8 Furio Pacini, M.D., 9 Martin Schlumberger, M.D., 10 Steven I. Sherman, M.D., 11 David L. Steward, M.D., 12 and R. Michael Tuttle, M.D. 13 Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the publication of the American Thyroid Association’s guidelines for the man- agement

2009 British Association of Endocrine and Thyroid Surgeons

272. Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review

Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review Yoo J, Cosby R, Driedger A CRD summary The conclusion that recombinant humanized thyroid (...) -stimulating hormone for radioablation preparation following total or near-total thyroidectomy in patients with papillary or follicular thyroid cancer was equivalent to thyroid hormone withdrawal should be viewed with caution; lack of significant difference is not the same as equivalence in efficacy. Bias was possible and results were based on poorer quality study designs. Authors' objectives To evaluate the therapeutic use of recombinant humanised thyroid-stimulating hormone (rhTSH) for radioiodine

2009 DARE.

273. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

274. Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review

Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

275. Pediatric thyroid fine-needle aspiration cytology: a meta-analysis

Pediatric thyroid fine-needle aspiration cytology: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

276. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis

Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

277. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study Full Text available with Trip Pro

High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study Overt and subclinical hyperthyroidism are both well-known independent risk factors for atrial fibrillation. We aimed to investigate the association of high-normal thyroid function with the development of atrial fibrillation in a prospective population-based study in the elderly.The association between thyroid-stimulating hormone (TSH) levels and atrial fibrillation was examined in 1426 subjects with TSH levels (...) ). The multivariate adjusted level of free thyroxine showed a graded association with risk of atrial fibrillation (HR, 1.62; 95% CI, 0.84-3.14, highest vs lowest quartile; P for trend, .06).Within the normal range of thyroid parameters, persons with high-normal thyroid function are at an increased risk of atrial fibrillation.

2008 EvidenceUpdates

278. Goitrous autoimmune thyroiditis in a pediatric population: a longitudinal study (Abstract)

Goitrous autoimmune thyroiditis in a pediatric population: a longitudinal study Patients with autoimmune thyroiditis can present with thyroid function that varies from euthyroidism to frank hypothyroidism or occasionally hyperthyroidism. Although there is a risk of progression from the euthyroid or subclinical hypothyroid state to frank hypothyroidism, the rate of progression is not known.Subjects with diffuse goiter and autoimmune thyroiditis were followed up to observe the rate (...) of deterioration in thyroid function from euthyroid and subclinical hypothyroid states to hypothyroidism.Patients who presented with goiter and autoimmune thyroiditis were grouped as those with euthyroidism, subclinical hypothyroidism, and overt hypothyroidism on the basis of levels of thyroxine and thyrotropin at presentation. Patients were followed up for a minimum duration of 24 months with periodic monitoring of thyroid function.Ninety-eight consecutive subjects (aged of 8-18 years) with a diagnosis

2008 EvidenceUpdates

279. Thyroid carcinoma.

Thyroid carcinoma. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse (NGC) has ended. Learn more

2008 Publication 1351

280. Maternal thyroid hypofunction and pregnancy outcome Full Text available with Trip Pro

Maternal thyroid hypofunction and pregnancy outcome To estimate whether maternal thyroid hypofunction is associated with complications.A total of 10,990 patients had first- and second-trimester serum assayed for thyroid-stimulating hormone (TSH), free thyroxine (freeT4), and antithyroglobulin and antithyroid peroxidase antibodies. Thyroid hypofunction was defined as 1) subclinical hypothyroidism: TSH levels above the 97.5th percentile and free T4 between the 2.5th and 97.5th percentiles or 2 (...) ) hypothyroxinemia: TSH between the 2.5th and 97.5th percentiles and free T4 below the 2.5th percentile. Adverse outcomes were evaluated. Patients with thyroid hypofunction were compared with euthyroid patients (TSH and free T4 between the 2.5th and 97.5th percentiles). Patients with and without antibodies were compared. Multivariable logistic regression analysis adjusted for confounders was used.Subclinical hypothyroidism was documented in 2.2% (240 of 10,990) in the first and 2.2% (243 of 10,990) in the second

2008 EvidenceUpdates